{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:41:39Z","timestamp":1789170099246,"version":"build-2803163510"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"am","delay-in-days":385,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-15-1-0627"],"award-info":[{"award-number":["W81XWH-15-1-0627"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-15-1-0622"],"award-info":[{"award-number":["W81XWH-15-1-0622"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-18-1-0029"],"award-info":[{"award-number":["W81XWH-18-1-0029"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019549","name":"Vanderbilt Institute of Nanoscale Science and Engineering, Vanderbilt University","doi-asserted-by":"publisher","award":["R01CA163499"],"award-info":[{"award-number":["R01CA163499"]}],"id":[{"id":"10.13039\/100019549","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01CA091664"],"award-info":[{"award-number":["U01CA091664"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5P30 CA68485-19"],"award-info":[{"award-number":["5P30 CA68485-19"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1S10RR027027631"],"award-info":[{"award-number":["1S10RR027027631"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA163499"],"award-info":[{"award-number":["R01CA163499"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R00CA194198"],"award-info":[{"award-number":["R00CA194198"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jconrel.2019.08.038","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T19:33:56Z","timestamp":1567712036000},"page":"257-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease"],"prefix":"10.1016","volume":"311-312","author":[{"given":"Joseph P.","family":"Vanderburgh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin A.","family":"Kwakwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Werfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa R.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Guelcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig L.","family":"Duvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7442-6085","authenticated-orcid":false,"given":"Julie A.","family":"Rhoades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2019.08.038_bib0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2008.05.044","article-title":"Osteotropic cancers: from primary tumor to bone","volume":"273","author":"Buijs","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0010","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0015","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0020","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I","article-title":"Mechanisms of bone metastasis","volume":"80","author":"Mundy","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bone.2010.07.015","article-title":"Advances in the biology of bone metastasis: how the skeleton affects tumor behavior","volume":"48","author":"Sterling","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0030","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00223-017-0353-5","article-title":"Bone-targeted therapies in cancer-induced bone disease","volume":"102","author":"Sousa","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0040","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/jbmr.2818","article-title":"Incidence of atypical femur fractures in cancer patients: the MD Anderson Cancer Center experience","volume":"31","author":"Edwards","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0045","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1634\/theoncologist.2016-0192","article-title":"Retrospective review of atypical femoral fracture in metastatic bone disease patients receiving denosumab therapy","volume":"22","author":"Yang","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0050","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0055","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-011-1429-y","article-title":"Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II\/III breast cancer","volume":"127","author":"Coleman","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10549-017-4308-3","article-title":"Combination breast cancer chemotherapy with doxorubicin and cyclophosphamide damages bone and bone marrow in a female rat model","volume":"165","author":"Fan","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0070","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bone.2014.02.018","article-title":"Consequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursors","volume":"63","author":"Green","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0075","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1101\/gad.938601","article-title":"Hedgehog signaling in animal development: paradigms and principles","volume":"15","author":"Ingham","year":"2001","journal-title":"Genes Dev."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0080","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nrm3598","article-title":"The mechanisms of hedgehog signalling and its roles in development and disease","volume":"14","author":"Briscoe","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0085","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nrc1229","article-title":"Hedgehog signalling in cancer formation and maintenance","volume":"3","author":"Pasca di Magliano","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0090","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1158\/0008-5472.CAN-04-0416","article-title":"Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer","volume":"64","author":"Kubo","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0095","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nature02962","article-title":"Hedgehog signalling in prostate regeneration, neoplasia and metastasis","volume":"431","author":"Karhadkar","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0100","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/sj.onc.1209860","article-title":"Frequent requirement of hedgehog signaling in non-small cell lung carcinoma","volume":"26","author":"Yuan","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0105","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-10-2745","article-title":"Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0110","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1158\/1078-0432.CCR-12-3654","article-title":"Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors","volume":"19","author":"Jimeno","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0115","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1158\/1078-0432.CCR-14-1116","article-title":"A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors","volume":"21","author":"Wagner","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0120","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-11-0923","article-title":"Hedgehog fights back: mechanisms of acquired resistance against smoothened antagonists","volume":"71","author":"Metcalfe","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0125","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ccell.2015.02.002","article-title":"Smoothened variants explain the majority of drug resistance in basal cell carcinoma","volume":"27","author":"Atwood","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0130","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/0008-5472.CAN-10-2993","article-title":"TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical hedgehog signaling","volume":"71","author":"Johnson","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0135","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10585-014-9682-1","article-title":"Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer","volume":"31","author":"Johnson","year":"2014","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0140","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1073\/pnas.0609699104","article-title":"Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists","volume":"104","author":"Lauth","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0145","doi-asserted-by":"crossref","first-page":"14132","DOI":"10.1073\/pnas.0907134106","article-title":"Small-molecule inhibitors reveal multiple strategies for hedgehog pathway blockade","volume":"106","author":"Hyman","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0150","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1158\/0008-5472.CAN-06-0452","article-title":"The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells","volume":"66","author":"Sterling","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0155","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3390\/cancers7030856","article-title":"The role of hedgehog signaling in tumor induced bone disease","volume":"7","author":"Cannonier","year":"2015","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0160","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15773","article-title":"EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells","volume":"8","author":"Neelakantan","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0165","doi-asserted-by":"crossref","first-page":"84286","DOI":"10.18632\/oncotarget.12483","article-title":"The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo","volume":"7","author":"Gonnissen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0170","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/1078-0432.CCR-13-2195","article-title":"Hedgehog-GLI signaling inhibition suppresses tumor growth in squamous lung cancer","volume":"20","author":"Huang","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0175","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0180","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","article-title":"Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications","volume":"200","author":"Wicki","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0185","doi-asserted-by":"crossref","first-page":"325ra317","DOI":"10.1126\/scitranslmed.aad2355","article-title":"Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo","volume":"8","author":"Ashton","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0190","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14292","article-title":"Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma","volume":"8","author":"Mizrachi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0195","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41467-017-01830-8","article-title":"T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity","volume":"8","author":"Schmid","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0200","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1158\/1078-0432.CCR-07-1385","article-title":"Targeted agents: the rules of combination","volume":"13","author":"Kwak","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0205","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jconrel.2012.07.042","article-title":"Poly(PS-b-DMA) micelles for reactive oxygen species triggered drug release","volume":"162","author":"Gupta","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0210","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.biomaterials.2016.03.028","article-title":"Fluorocoxib a loaded nanoparticles enable targeted visualization of cyclooxygenase-2 in inflammation and cancer","volume":"92","author":"Uddin","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0215","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/1535-7163.MCT-11-0341","article-title":"A polymeric nanoparticle encapsulated small-molecule inhibitor of hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to smoothened antagonists","volume":"11","author":"Chenna","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0220","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0225","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1073\/pnas.1418494112","article-title":"Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance","volume":"112","author":"Wei","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0230","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/annonc\/mdm374","article-title":"Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer","volume":"18","author":"Kim","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0235","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jconrel.2017.04.043","article-title":"Smart chemistry-based nanosized drug delivery systems for systemic applications: a comprehensive review","volume":"258","author":"Ramasamy","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0240","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1016\/j.actbio.2013.01.041","article-title":"Dual pH- and temperature-responsive microparticles for protein delivery to ischemic tissues","volume":"9","author":"Joshi","year":"2013","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0245","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1021\/bm501394m","article-title":"Dual MMP7-proximity-activated and folate receptor-targeted nanoparticles for siRNA delivery","volume":"16","author":"Li","year":"2014","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0250","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.biomaterials.2014.11.016","article-title":"ROS-responsive microspheres for on demand antioxidant therapy in a model of diabetic peripheral arterial disease","volume":"41","author":"Poole","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0255","first-page":"40","article-title":"The combined effect of tumor-produced parathyroid hormone-related protein and transforming growth factor-alpha enhance hypercalcemia in vivo and bone resorption in vitro","volume":"77","author":"Guise","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0260","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccr.2009.05.017","article-title":"Latent bone metastasis in breast cancer tied to src-dependent survival signals","volume":"16","author":"Zhang","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0265","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1039\/C5TB02747K","article-title":"Substrate modulus regulates osteogenic differentiation of rat mesenchymal stem cells through integrin \u03b21 and BMP receptor type IA","volume":"4","author":"Guo","year":"2016","journal-title":"J. Mater. Chem. B Mater. Biol. Med."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0270","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI117979","article-title":"The role of cadherin in the generation of multinucleated osteoclasts from mononuclear precursors in murine marrow","volume":"95","author":"Mbalaviele","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0275","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood.V96.5.1953","article-title":"Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity","volume":"96","author":"Michigami","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0280","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.nano.2017.04.003","article-title":"Quantitative microscopy-based measurements of circulating nanoparticle concentration using microliter blood volumes","volume":"13","author":"Tietjen","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0285","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/bonekey.2016.31","article-title":"Murine models of breast cancer bone metastasis","volume":"5","author":"Wright","year":"2016","journal-title":"Bonekey Rep."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0290","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1210\/mend.16.2.0775","article-title":"Nuclear transport of parathyroid hormone (PTH)-related protein is dependent on microtubules","volume":"16","author":"Lam","year":"2002","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0295","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/jbmr.3291","article-title":"Autocrine and paracrine regulation of the murine skeleton by osteocyte-derived parathyroid hormone-related protein","volume":"33","author":"Ansari","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0300","first-page":"1454","article-title":"Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications","volume":"59","author":"Sparreboom","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0305","doi-asserted-by":"crossref","first-page":"14896","DOI":"10.1021\/ja507626y","article-title":"Cell protective, ABC triblock polymer-based thermoresponsive hydrogels with ROS-triggered degradation and drug release","volume":"136","author":"Gupta","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0310","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/acsbiomaterials.6b00804","article-title":"Drug-free ROS sponge polymeric microspheres reduce tissue damage from ischemic and mechanical injury","volume":"4","author":"O'Grady","year":"2018","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0315","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1089\/ten.tea.2016.0495","article-title":"Reactive oxygen species shielding hydrogel for the delivery of adherent and nonadherent therapeutic cell types","volume":"23","author":"Dollinger","year":"2017","journal-title":"Tissue Eng. Part A"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0320","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/bc00031a006","article-title":"A branched monomethoxypoly(ethylene glycol) for protein modification","volume":"6","author":"Monfardini","year":"1995","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0325","doi-asserted-by":"crossref","first-page":"15231","DOI":"10.1073\/pnas.0904378106","article-title":"In situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics","volume":"106","author":"Gao","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0330","doi-asserted-by":"crossref","first-page":"16432","DOI":"10.1073\/pnas.1006044107","article-title":"In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation","volume":"107","author":"Gao","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0335","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.2174\/0929867324666170711114336","article-title":"The role of oxidative stress modulators in breast cancer","volume":"25","author":"Gurer-Orhan","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0340","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jconrel.2017.03.389","article-title":"Combinatorial optimization of PEG architecture and hydrophobic content improves ternary siRNA polyplex stability, pharmacokinetics, and potency in vivo","volume":"255","author":"Werfel","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0345","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1126\/science.1203543","article-title":"A perspective on cancer cell metastasis","volume":"331","author":"Chaffer","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0350","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0360","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1158\/1078-0432.CCR-09-0426","article-title":"High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties","volume":"15","author":"Pozzi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0365","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00223-008-9104-y","article-title":"Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro","volume":"82","author":"Idris","year":"2008","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0370","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-11-0950","article-title":"Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma","volume":"18","author":"Xu","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0375","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1158\/0008-5472.CAN-17-1225","article-title":"Bone-induced expression of integrin beta3 enables targeted nanotherapy of breast cancer metastases","volume":"77","author":"Ross","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0380","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.biomaterials.2017.10.053","article-title":"Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis","volume":"154","author":"Yamashita","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0385","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/1078-0432.CCR-15-1421","article-title":"Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies","volume":"22","author":"Hu","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0390","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1007\/s00198-016-3672-x","article-title":"Effects of doxorubicin administration on bone strength and quality in sedentary and physically active Wistar rats","volume":"27","author":"Fonseca","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0395","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1158\/0008-5472.CAN-10-4173","article-title":"Blocking hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells","volume":"71","author":"Mazumdar","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0400","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.addr.2010.03.011","article-title":"Tumor delivery of macromolecular drugs based on the EPR effect","volume":"63","author":"Torchilin","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0405","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.biomaterials.2015.06.026","article-title":"Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin beta3 and TGF-beta receptor type II","volume":"64","author":"Page","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0410","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jmbbm.2015.06.023","article-title":"Mechanics of intact bone marrow","volume":"50","author":"Jansen","year":"2015","journal-title":"J. Mech. Behav. Biomed. Mater."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015451","article-title":"Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells","volume":"5","author":"Ruppender","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0420","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ccr.2010.12.022","article-title":"Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells","volume":"19","author":"Sethi","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0425","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ccell.2017.11.002","article-title":"Therapeutic antibody targeting tumor- and osteoblastic niche-derived jagged1 sensitizes bone metastasis to chemotherapy","volume":"32","author":"Zheng","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2019.08.038_bib0430","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ncb3464","article-title":"A ROR1-HER3-lncRNA signalling axis modulates the hippo-YAP pathway to regulate bone metastasis","volume":"19","author":"Li","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0435","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/nm.3391","article-title":"Tumor metastasis: moving new biological insights into the clinic","volume":"19","author":"Wan","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2019.08.038_bib0440","first-page":"3059","article-title":"Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites","volume":"51","author":"Powell","year":"1991","journal-title":"Cancer Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919305322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919305322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:43:06Z","timestamp":1778730186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365919305322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":88,"alternative-id":["S0168365919305322"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.08.038","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.08.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}